Resumen de las cotizaciones máximas, mínimas y variaciones del argenx
Precios históricos de las acciones
Precio actual de la acción	€864.20
Máximo en las últimas 52 semanas	€903.00
Mínimo de 52 semanas	€568.40
Beta	-0.040
Cambio en 1 mes	7.43%
Variación en 3 meses	24.49%
Cambio de 1 año	46.47%
Variación en 3 años	84.03%
Variación en 5 años	201.22%
Variación desde la OPV	10,839.24%

Noticias y actualizaciones recientes

Actualización de narrativa • Aug 11

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

The analyst fair value estimate for argenx has increased from €991 to approximately €1,093, with analysts citing a series of higher Street price targets and positive views on Vyvgart performance, the Forte Biosciences acquisition, and the broader immunology pipeline. Analyst Commentary Recent Street commentary on argenx points to strong interest in Vyvgart execution, expanding autoimmune indications and the Forte Biosciences acquisition, with many bullish analysts revisiting their models and price targets through mid 2026.

Actualización de narrativa • Jul 28

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Analysts have nudged their fair value estimate for argenx higher to about €906 from roughly €887, reflecting a slightly lower discount rate and marginally improved long term profitability assumptions, partly supported by a wave of price target increases after the Forte Biosciences acquisition and stronger Vyvgart performance in recent Q2 results. Analyst Commentary Recent research views on argenx cluster around two themes.

Recent updates

Actualización de narrativa • Aug 11

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

Actualización de narrativa • Jul 28

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Actualización de narrativa • Jul 14

ARGX: Myositis Phase 3 Data Will Drive Next Leg Of Upside

The analyst price target for argenx has been raised by approximately €18 to reflect slightly higher modeled fair value and modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, supported by recent Street research that highlights myositis as a key potential value driver for Vyvgart. Analyst Commentary Recent Street research on argenx continues to cluster around Vyvgart and its potential in myositis, with multiple firms updating valuation models and price targets.

Actualización de narrativa • Jun 30

ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power

Analysts have nudged their average price targets for argenx higher, citing a series of recent target increases into the €1,059 to about €1,291 range and arguing that the market may still underappreciate the potential of Vyvgart in autoimmune myositis and related indications. Analyst Commentary Recent research on argenx centers on how Vyvgart and the broader myositis program could influence the company’s long term value, with several firms updating their models ahead of key Phase 3 readouts.

Actualización de narrativa • Jun 16

ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations

The analyst fair value estimate for argenx has been revised from €614.80 to €644.90 as analysts factor in higher Street price targets and upcoming Phase 3 myositis and ALKIVIA study readouts for Vyvgart and efgartigimod. Analyst Commentary on argenx Recent Street research around argenx highlights a mix of optimism on the clinical pipeline and caution on execution and valuation, giving investors a more balanced picture of risk around Vyvgart and efgartigimod ahead of the Phase 3 myositis and ALKIVIA readouts.

Actualización de narrativa • Jun 02

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

Analysts have nudged their blended price target for argenx higher to about €1,000, reflecting incremental target increases up to €1,291, as they point to upcoming Vyvgart and efgartigimod Phase 3 data and ongoing profitability as key supports for the updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on argenx, pointing to upcoming clinical readouts and recent profitability as key pieces of the story rather than short term trading factors.

Nueva narrativa • May 20

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.

Actualización de narrativa • May 14

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.

Actualización de narrativa • Apr 29

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.

Actualización de narrativa • Apr 15

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.

Actualización de narrativa • Apr 01

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.

Actualización de narrativa • Mar 17

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.

Actualización de narrativa • Mar 03

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.

Actualización de narrativa • Feb 17

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.

Actualización de narrativa • Feb 03

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.

Actualización de narrativa • Jan 20

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.

Actualización de narrativa • Jan 06

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.

Actualización de narrativa • Dec 15

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.

Actualización de narrativa • Nov 30

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.

Actualización de narrativa • Nov 16

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.

Actualización de narrativa • Nov 02

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.

Actualización de narrativa • Sep 25

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.

Actualización de narrativa • Aug 29

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.

Actualización de narrativa • Aug 06

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.

Nueva narrativa • Apr 27

Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach

Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.

Rentabilidad de los accionistas

	ARGX	BE Biotechs	Mercado BE
7D	1.1%	2.8%	0.3%
1Y	46.5%	26.8%	18.6%

Rentabilidad vs. Industria: ARGX superó a la industria Belgian Biotechs, que obtuvo un rendimiento del 26.8% el año pasado.

Rentabilidad vs. Mercado: ARGX superó al mercado Belgian, que obtuvo un rendimiento del 18.6% el año pasado.

Volatilidad de los precios

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement	7.0%
Biotechs Industry Average Movement	7.3%
Market Average Movement	3.6%
10% most volatile stocks in BE Market	7.6%
10% least volatile stocks in BE Market	2.0%

Precio estable de las acciones: El precio de las acciones de ARGX ha sido volátil durante los últimos 3 meses en comparación con el mercado Belgian.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ARGX(7%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Belgian.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2008	1,863	Karen Massey	argenx.com

argenx SE, empresa biofarmacéutica en fase comercial, desarrolla diversas terapias para el tratamiento de enfermedades autoinmunes en Estados Unidos, Japón, China, Países Bajos e internacionalmente. La empresa ofrece VYGART y VYGART HYTRULO para tratar la miastenia grave generalizada (GMG), la trombocitopenia inmunitaria (PTI) y la polineuropatía desmielinizante inflamatoria crónica (PDIC). También desarrolla efgartigimod para el tratamiento de la gMG seronegativa y ocular, las enfermedades oculares tiroideas, la PTI, la miositis, la enfermedad de Sjögren, la nefropatía lúpica, la esclerosis sistémica, el rechazo mediado por anticuerpos y la encefalitis autoinmune; empasiprubart contra la neuropatía motora multifocal, la PDIC, el retraso de la función del injerto y la dermatomiositis; y ARGX-119 contra el síndrome miasténico congénito, la esclerosis lateral amiotrófica y la atrofia muscular espinal.

Resumen de fundamentos de argenx SE

¿Cómo se comparan los beneficios e ingresos de argenx con su capitalización de mercado?
Estadísticas fundamentales de ARGX
Capitalización bursátil	€56.41b
Beneficios(TTM)	€1.47b
Ingresos (TTM)	€4.56b

36.8x

Ratio precio-beneficio (PE)

11.9x

Ratio precio-ventas (PS)

¿Está ARGX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ARGX
Ingresos	US$5.32b
Coste de los ingresos	US$2.18b
Beneficio bruto	US$3.14b
Otros gastos	US$1.42b
Beneficios	US$1.72b

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Oct 22, 2026

Beneficios por acción (BPA)	27.42
Margen bruto	59.07%
Margen de beneficio neto	32.27%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ARGX a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/08/24 21:30
Precio de las acciones al final del día	2026/08/24 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

argenx SE está cubierta por 52 analistas. 28 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
null null	Baird
Colleen Kusy	Baird
Joel Beatty	Baird

argenx (ARGX) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

Top Community Narratives

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Top Community Narratives

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Top Analyst Narratives

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets

Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins

Competidores de argenx SE

UCB

BeOne Medicines

Alnylam Pharmaceuticals

PharmaEssentia

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Investor sentiment improves as stock rises 16%

Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis

Vyvgart Achieves Positive Phase 3 Results in Autoimmune Myositis With No Approved Therapies

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

argenx SE (ENXTBR:ARGX) entered into a definitive agreement to acquire Forte Biosciences, Inc. (NasdaqCM:FBRX) for $1.6 billion.

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Recent updates

Investor sentiment improves as stock rises 16%

Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis

Vyvgart Achieves Positive Phase 3 Results in Autoimmune Myositis With No Approved Therapies

ARGX: Myositis Phase 3 Readouts And Forte Deal Will Drive Future Repricing

argenx SE (ENXTBR:ARGX) entered into a definitive agreement to acquire Forte Biosciences, Inc. (NasdaqCM:FBRX) for $1.6 billion.

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Argenx to Acquire Forte Biosciences in $2.2 Billion Immunology Pipeline Expansion

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2026 Results on Feb 25, 2027

argenx Collaborates With Chai Discovery for Early Access to AI Antibody Platform

ARGX: Myositis Phase 3 Data Will Drive Next Leg Of Upside

New minor risk - Share price stability

ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power

ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations

Argenx Surges as Vyvgart Gains FDA Approval for All Adult Generalized Myasthenia Gravis Patients

Argenx Unveils Vyvgart Data for Myositis and Sjogren’s at EULAR 2026

Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’s Disease At EULAR 2026

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

First quarter 2026 earnings: EPS exceeds analyst expectations

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

Insufficient new directors

Full year 2025 earnings: EPS exceeds analyst expectations

argenx SE, Annual General Meeting, May 06, 2026

Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis

argenx SE to Report Q1, 2026 Results on May 07, 2026

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

argenx SE Announces Management Changes

argenx SE Announces the Retirement of Peter Verhaeghe from the Board of Directors

argenx SE Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Independent Chairman of the Board exercised options and sold €1.5m worth of stock

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Independent Vice Chairman exercised options and sold €3.7m worth of stock

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Independent Vice Chairman exercised options and sold €3.5m worth of stock

Consensus EPS estimates increase by 11%

argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook